Medetomidine alkyne

• Bioorthogonal Reactivity – Features a terminal alkyne group compatible with copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) for site-specific conjugation.
• Receptor Selectivity Preserved – Retains high affinity and selectivity for α2-adrenergic receptors, maintaining the pharmacological profile of native medetomidine.
• Live-Cell and In Vivo Compatibility – Suitable for use in live-cell assays, receptor localization studies, and in vivo pharmacokinetic tracking.

Medetomidine Alkyne is a chemically modified analog of medetomidine, a potent and highly selective α2-adrenergic receptor agonist, engineered to include a terminal alkyne group for bioorthogonal labeling via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). This structural modification preserves the native receptor-binding affinity and pharmacological activity of medetomidine while introducing a bioorthogonal reactive handle, enabling covalent conjugation to azide-functionalized probes, tags, or reporter molecules. The resulting conjugates are valuable for a broad range of chemical biology applications, including receptor mapping, target validation, and pharmacokinetic profiling.

The alkyne-functionalized scaffold facilitates high-efficiency, site-specific labeling under mild conditions, making it suitable for use in live-cell environments, tissue preparations, and in vivo studies. Medetomidine Alkyne is particularly advantageous in ligand-directed strategies, such as affinity-based protein profiling and target-specific enrichment, where selective engagement of α2-adrenergic receptors is coupled with downstream detection or isolation. Its compatibility with fluorescence imaging, proteomics, and drug delivery systems supports mechanistic investigations of receptor localization, trafficking, and signal transduction within native biological contexts.